Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. Among authors: radue ew. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis.
Bendfeldt K, Blumhagen JO, Egger H, Loetscher P, Denier N, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Gass A, Hirsch J, Kappos L, Nichols TE, Radue EW, Borgwardt SJ. Bendfeldt K, et al. Among authors: radue ew. Hum Brain Mapp. 2010 Oct;31(10):1542-55. doi: 10.1002/hbm.20951. Hum Brain Mapp. 2010. PMID: 20108225 Free PMC article.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects.
Bendfeldt K, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Nichols TE, Barkhof F, Vrenken H, Roosendaal SD, Geurts JJ, Radue EW, Borgwardt SJ. Bendfeldt K, et al. Among authors: radue ew. Hum Brain Mapp. 2012 May;33(5):1225-45. doi: 10.1002/hbm.21279. Epub 2011 Apr 29. Hum Brain Mapp. 2012. PMID: 21538703 Free PMC article.
Prediction of long-term disability in multiple sclerosis.
Schlaeger R, D'Souza M, Schindler C, Grize L, Dellas S, Radue EW, Kappos L, Fuhr P. Schlaeger R, et al. Among authors: radue ew. Mult Scler. 2012 Jan;18(1):31-8. doi: 10.1177/1352458511416836. Epub 2011 Aug 25. Mult Scler. 2012. PMID: 21868486
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Devonshire V, et al. Among authors: radue ew. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Lancet Neurol. 2012. PMID: 22494956 Clinical Trial.
210 results